NanoViricides Inc. (NNVC) stock rises during after-hour, despite any update

Related Topics

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

NanoViricides Inc. (NASDAQ: NNVC) stock surged by 63.32% at last close while the NNVC stock price soars by 3.71% in the after-hours trading session yet the company has not provided any update on this.  NanoViricides is a firm in the early stages of development that develops antiviral nanoparticles. The Company’s innovative nanoviricide medication candidates are designed to specifically attack and deconstruct encapsulated virus particles.

NNVC stock’ Recent Development

NanoViricides recently stated that it has finished the stage of licencing the human Coronavirus field from TheraCour Pharma for medication research and commercialization. Recently, on September 8, 2021, the Company signed a licensing deal with TheraCour Pharma, Inc. for the field of antiviral medicines for coronavirus-derived human illnesses.

Antiviral medications to cure SARS-CoV-2 and its variants, which inflict the COVID-19 disease and have resulted in a global pandemic that continues to rampage around the world, wave after wave, as new variants emerge and take root. The licence did not need any upfront cash payment, as well as the remuneration terms, were usually identical with previous agreements. However, NanoViricides is actively focusing on human clinical trials for its two COVID-19 main therapeutic candidates, NV-CoV-2- and NV-CoV-2-R. The Company thinks that the necessary preclinical work for putting these medications into human trials is nearly complete.

Furthermore,

The company considers that these broad-spectrum anti-coronavirus medications will be able to remain viable even as the virus begins to mutate and evolve into a variety of dangerous versions. As additional SRAS-CoV-2 variants have appeared, antibody protection provided by vaccines and the efficacy of antibody medicines has continued to deteriorate. The company also thinks that their patent-pending anti-viral nanomachine technology will solve these problems. However, they believe that they are in a good position to deliver a COVID-19 infection treatment as an outpatient oral drug. In animal trials, NNVC discovered that its anti-COVID-19 medicines had substantial antiviral activity when given orally.

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest Posts